Meeting Banner
Abstract #3874

Dynamic Contrast Enhanced Magnetic Resonance Imaging Evaluates Therapeutic Mechanism of nab-Paclitaxel in Pancreatic Cancer Patient Derived Xenograft Mouse Models.

Hyunki Kim 1 , Sharon Samuel 1 , Marie Warren 1 , Guihua Zhai 1 , William Grizzle 1 , Denise Oelschlager 1 , Pedro Lopez-Casas 2 , Manuel Hidalgo 2 , Joy Kovar 3 , Kurt Zinn 1 , and Donald Buchsbaum 1

1 University of Alabama at Birmingham, Birmingham, AL, United States, 2 Spanish National Cancer Research Center, Madrid, Spain, 3 LI-COR Biosciences, Nebraska, United States

Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) was employed to identify the therapeutic mechanism of nab-paclitaxel in pancreatic cancer patient derived xenograft mouse models. DCE-MRI demonstrated that nab-paclitaxel did not significantly increase the microvascular perfusion in tumor xenografts for 3 weeks of nab-paclitaxel treatment, although gemcitabine did. Also, histologic analysis showed that tumor stroma was not significantly reduced by nab-paclitaxel, but high tumor retention of fluorophore labeled nab-paclitaxel was observed. Therefore the significant clinical benefits of nab-paclitaxel may result from its effective delivery into tumors in pancreatic cancer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here